Article
Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19
bioRxiv: the preprint server for biology · 2020 · Nirmitee Mulgaonkar, author Haoqi Wang, author Samavath Mallawarachchi, author Sandun Fernando, author Byron Martina, author Daniel Ruzek, author
Key facts
| Title | Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19 |
|---|---|
| First author | Nirmitee Mulgaonkar, author Haoqi Wang, author Samavath Mallawarachchi, author Sandun Fernando, author Byron Martina, author Daniel Ruzek, author |
| Journal | bioRxiv : the preprint server for biology |
| Published | Aug 18, 2020 |
| DOI | 10.1101/2020.06.18.158196 |
| Devices mentioned | K912666 |
| Product codes mentioned | LIQ |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1